H.C. Wainwright raised the firm’s price target on UroGen Pharma to $64 from $60 and keeps a Buy rating on the shares after the UGN-102 regulatory submission was accepted for review. The firm says UGN-102 could become the first FDA-approved medicine for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer. It increased its probability of regulatory approval in the U.S. for the candidate to 90% from 85%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma announces FDA acceptance of new drug application for UGN-102
- UroGen Pharma initiated with a Buy at EF Hutton
- UroGen Pharma Announces CFO Transition and Compensation Details
- UroGen Pharma CFO Don Kim departs, Chris Degnan succeeds
- UroGen Pharma: Patient dosed in mitomycin-based UGN-103 trial for LG-IR-NMIBC
Questions or Comments about the article? Write to editor@tipranks.com